CRT 2025

Late-Breaking Clinical Trials Coronary

Paclitaxel-Coated Balloon Versus Uncoated Balloon for Coronary In-Stent Restenosis | Two-Year Outcomes of the AGENT IDE Trial

Speaker(s)

• 

  Jeffrey W. Moses, MD, FSCAI

  John and Myrna Daniels Professor of Cardiology
  Columbia University Medical Center
  New York, New York, United States

  Disclosure(s): Covanos Inc.: Stock-privately held company (Ongoing); Orchestra Biomed: Stock-privately held company (Ongoing); OSTIAL Corp: Stock-privately held company (Ongoing); Weightless Lead: Stock-privately held company (Ongoing); Xenter Inc: Stock-privately held company (Ongoing)